|
© 2007 American Academy of Neurology Evidence for neuroprotection and remyelination using imaging techniquesFrom the Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada. Address correspondence and reprint requests to Dr. Douglas L. Arnold, Montreal Neurological Institute, 3801 University Street, Montreal, Quebec, H3A 2B4, Canada doug{at}mrs.mni.mcgill.ca MRI is used routinely in clinical practice and pharmaceutical trials to measure disease activity and assess the effects of treatment in multiple sclerosis. Conventional MRI techniques sensitively detect inflammation, demyelination, and tissue injury. Less conventional imaging modalities, such as magnetic resonance spectroscopy and magnetization transfer imaging, and advanced image processing to quantify structural changes can provide more specific and inherently quantitative markers of the pathologic processes underlying the accumulation of disease burden and the progression of clinical disability. Together, these techniques can assess both the anti-inflammatory and the neuroprotective effects of immunomodulatory therapies.
This supplement was supported by an educational grant from Teva Neuroscience. BioScience Communications contributed to the editorial refinement of this article and to the production of this supplement. Authors may have accepted honoraria for their supplement contributions. Disclosure:. The author reports no conflict of interest. Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology. This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||
